Skip to main content
. 2023 Sep 22;12(10):2887–2897. doi: 10.21037/tcr-23-422

Table 1. Clinical features of patients.

Clinical features Training cohort (n=2,208) Test cohort (n=922)
Age (years) 73 [66, 79] 74 [68, 80]
Sex
   Male 1,736 (78.62) 708 (76.79)
   Female 472 (21.38) 214 (23.21)
History of malignancy
   No 1,662 (75.27) 664 (72.02)
   Yes 546 (24.73) 258 (27.98)
Pathology
   Epithelioid mesothelioma 1,452 (65.76) 624 (67.68)
   Sarcomatoid mesothelioma 419 (18.98) 151 (16.38)
   Biphasic mesothelioma 337 (15.26) 147 (15.94)
T
   T1 696 (31.52) 322 (34.92)
   T2 496 (22.46) 182 (19.74)
   T3 409 (18.52) 147 (15.94)
   T4 607 (27.49) 271 (29.39)
N
   N0 1,446 (65.49) 614 (66.59)
   N1 118 (5.34) 146 (15.84)
   N2 581 (26.31) 143 (15.51)
   N3 63 (2.85) 19 (2.06)
M
   M0 1,835 (83.11) 663 (71.91)
   M1 373 (16.89) 259 (28.09)
Surgery
   No 1,396 (63.22) 626 (67.90)
   Yes 812 (36.78) 296 (32.10)
Radiotherapy
   No 1,881 (85.19) 795 (86.23)
   Yes 327 (14.81) 127 (13.77)
Chemotherapy
   No 951 (43.07) 355 (38.50)
   Yes 1,257 (56.93) 567 (61.50)
Survival time (months) 10 [4, 22] 8 [3, 16]

Data are presented as median [interquartile range] or n (%).